FansUnite Entertainment Issues Statement Following the Passing of Bill C-218 By House of Commons

The Senate will now conduct the reading and adoption of Bill C-218 in order to legalize single event sports wagering in Canada

FansUnite Entertainment Inc. (CSE: FANS) (OTCQB: FUNFF) ("FansUnite" or the "Company") CEO Scott Burton issued the following statement after the House of Commons passed Bill C-218 on April 22, 2021. Bill C-218 or also known as The Safe and Regulated Sports Betting Act would make betting on individual sport events legal in Canada.

"We applaud the Canadian House of Commons for advancing the legislation to legalize single event sports betting, with many members expressing their support for Bill C-218," said Scott Burton, CEO of FansUnite. "This is another major step forward which we expect to benefit not only companies like ours, but to the growth of the entire Canadian gambling industry."

Bill C-218 now moves to the Senate for reading and adoption before moving to the Governor-General for Royal Assent.

About FansUnite Entertainment Inc.

FansUnite is a sports and entertainment company, focusing on technology related to regulated and lawful online gaming and other related products. The principal business is operating the FansUnite Sportsbook and the website of its wholly-owned subsidiary, McBookie Limited, offering online gaming services to the UK market. FansUnite is also a provider of technology solutions, products and services in the gaming and entertainment industry and looks to acquire technology platforms and assets with high-growth potential in new or developing markets.

For further information, please contact:

Prit Singh, Investor Relations at FansUnite
ir@fansunite.com
(905) 510-7636

Scott Burton, Chief Executive Officer of FansUnite
scott@fansunite.com

Darius Eghdami, President of FansUnite
darius@fansunite.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDERS HAVE REVIEWED ‎OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD-LOOKING STATEMENTS : Certain information contained herein may constitute "forward-‎‎‎looking information" under Canadian securities legislation. Generally, forward-looking information can be ‎‎‎identified by the use of forward-looking terminology such as "believes," "belief," "expects," "intends," ‎‎‎‎"anticipates," "potential," "should," "may," "will," "plans," "continue" or similar expressions to be uncertain ‎‎‎and forward-looking. Forward-looking statements may include, without limitation, statements relating to ‎‎‎future outlook and anticipated events such as: Bill C-218 receiving royal assent, the effect of Bill C-128 on online gaming activities, the ability of FansUnite to implement their Canadian licensing strategy; FansUnite's ability to ‎fulfill technology needs with its ‎platform; business development ‎plans of ‎FansUnite; the Company's unique portfolio of assets; and discussion of future plans, ‎projections, ‎objectives, estimates ‎and forecasts and the timing related thereto. Forward-looking statements ‎are based ‎on the Company's ‎estimates and are subject to known and unknown risks, uncertainties and ‎other factors ‎that may cause the ‎actual results, level of activity, performance or achievements of ‎FansUnite to be ‎materially different from ‎those expressed or implied by such forward-looking statements or ‎forward-looking ‎information. Additional ‎information regarding the risks and uncertainties relating to the ‎Company's business ‎are contained under ‎the heading "Risk Factors" in the Company's Non-Offering ‎Prospectus dated March 27, ‎‎2020 filed on its ‎issuer profile on SEDAR at www.sedar.com and risks related ‎to global pandemics, ‎including the novel ‎coronavirus (COVID-19) global health pandemic, and the spread of ‎other viruses or ‎pathogens and influence ‎of macroeconomic developments. Accordingly, readers should not ‎place undue ‎reliance on forward-looking ‎statements and forward-looking information. The forward-looking ‎statements in ‎this news release are made ‎as of the date of this release. FansUnite disclaims and does not ‎undertake to ‎update or revise any forward-‎looking statements or forward-looking information, whether as a ‎result of new ‎information, future events or ‎otherwise, except as required by applicable securities laws.‎

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/81529

News Provided by Newsfile via QuoteMedia

FansUnite CSE:FANS Emerging Tech Investing

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ("CT26"), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.

In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is pleased to announce the establishment of its new Advisory Board. The Advisory Board will collaborate with management and the board of directors to enhance the Company's strategic direction, provide expert guidance on its commercial initiatives, offer industry insights, and shape and accelerate innovations.

As the inaugural member of the Advisory Board, Syntheia welcomes Mr. John Kirk, a leader in the travel industry. The travel sector represents a potentially significant growth market for the Company's technology.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is transforming customer service by delivering an innovative solution that uses natural language processing (NLP) to handle inbound telephone calls with virtual assistants. Since its beta launch in June 2023, Syntheia has processed over 750,000 conversations, bringing new levels of efficiency and engagement to businesses in diverse industries.

Companies like Georgetown Hyundai, Palmieri Furniture, Campio Furniture, and Pay N Go have all embraced Syntheia's platform, highlighting its positive impact on sales and customer satisfaction.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Zero Candida Technologies Inc. Opens the Market

Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.

Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.

Please refer to the Company's website here.

MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
victoria@zero-candida.com
416-706-0332

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

FansUnite Entertainment Issues Statement Following the Passing of Bill C-218 By House of Commons

Latest News

Latest Press Releases

Related News

TOP STOCKS